Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, has announced a proposed public offering of $150.0 million of shares of its common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock.
The net proceeds from the proposed offering, together with its existing cash, cash equivalents, and marketable securities, will be used to fund the research and development of its product candidates and other development programs, as well as for working capital and other general corporate purposes.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the proposed offering. The securities are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on August 22, 2025.
Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ras/mapk pathway-driven cancers. The company's scientific advisory board includes the world’s leading experts in the ras/mapk pathway, positioning them to achieve their mission of erasing cancer.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. As a result of these announcements, the company's shares have moved 0.63% on the market, and are now trading at a price of $9.62. For the full picture, make sure to review Erasca's 8-K report.
